Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

MicroRNA-mediated mechanisms of lung adenocarcinoma development in non-smokers

EF 2014-15

Résumé
Lung cancer is the most common cause of cancer related death worldwide. Cigarette smoking is the primary cause of lung cancer; however, a striking 25% of lung cancer patients are non-smokers. In fact, if lung cancer in non-smokers was classified as a separate disease, it would rank among the top ten most fatal cancers. Emerging research suggests that lung cancer in non-smokers is a distinct disease that develops through different mechanisms than cancer induced by cigarette smoke. In Canada, the proportion of non-smokers being diagnosed with lung cancer is on the rise; thus, there is an urgent need for an improved understanding of lung cancer biology in non-smokers. It's been shown that recently discovered molecules called microRNAs (small particles of RNA that fine-tune mammalian protein production) play a crucial role in lung cancer progression. Cancer cells often modify microRNA levels to their advantage in order to drive tumour growth and enable biological immortality. The goal of our study is to explore how smoking status can effect microRNA activity in lung cancer cells. We hypothesize that cancer cells in non-smokers harbour distinct combinations of microRNAs compared to smokers and that these different microRNA profiles uniquely influence cancer development. By discovering key molecular features altered in non-smoker cancer cells, we can better understand how to diagnose and treat lung cancer patients who have no history of smoking.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
331273
Name
Rowbotham David A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
MicroRNA-mediated mechanisms of lung adenocarcinoma development in non-smokers
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Gene Expression; Lung Cancer; Lung Cancer Prognosis; Lung Cancer Therapy; Microrna; Mirna Target Prediction; Non-Smokers; Pathway Analysis; Tcga Sequencing Data
Abstract
Lung cancer is the most common cause of cancer related death worldwide. Cigarette smoking is the primary cause of lung cancer; however, a striking 25% of lung cancer patients are non-smokers. In fact, if lung cancer in non-smokers was classified as a separate disease, it would rank among the top ten most fatal cancers. Emerging research suggests that lung cancer in non-smokers is a distinct disease that develops through different mechanisms than cancer induced by cigarette smoke. In Canada, the proportion of non-smokers being diagnosed with lung cancer is on the rise; thus, there is an urgent need for an improved understanding of lung cancer biology in non-smokers. It's been shown that recently discovered molecules called microRNAs (small particles of RNA that fine-tune mammalian protein production) play a crucial role in lung cancer progression. Cancer cells often modify microRNA levels to their advantage in order to drive tumour growth and enable biological immortality. The goal of our study is to explore how smoking status can effect microRNA activity in lung cancer cells. We hypothesize that cancer cells in non-smokers harbour distinct combinations of microRNAs compared to smokers and that these different microRNA profiles uniquely influence cancer development. By discovering key molecular features altered in non-smoker cancer cells, we can better understand how to diagnose and treat lung cancer patients who have no history of smoking.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rowbotham, David A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~